Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade.

The clinical study will assess the safety and tolerability of escalating intra-tumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

Metastatic or advanced tumors Including:

  • TNBC 2 line or >
  • HNSCC 3 line or >
  • NHL 3 line or >
  • Urothelial PD-L-, 1st line
  • Urothelial 2nd line
  • Cutaneous melanoma

Inclusions/Exclusions: Measurable disease RECIST or Cheson 2016 criteria. ECOG 0-1.

Learn More.